hVIVO (HVO) Competitors GBX 10.05 +0.05 (+0.46%) As of 10:19 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesBuy This Stock HVO vs. VRP, AVCT, ARIX, CIR, BVXP, OBI, 4BB, TILS, VSN, and SCLPShould you be buying hVIVO stock or one of its competitors? The main competitors of hVIVO include Verona Pharma plc (VRP.L) (VRP), Avacta Group (AVCT), Arix Bioscience (ARIX), Circassia Group (CIR), Bioventix (BVXP), Ondine Biomedical (OBI), 4basebio (4BB), Tiziana Life Sciences (TILS), Verseon (VSN), and Scancell (SCLP). These companies are all part of the "biotechnology" industry. hVIVO vs. Its Competitors Verona Pharma plc (VRP.L) Avacta Group Arix Bioscience Circassia Group Bioventix Ondine Biomedical 4basebio Tiziana Life Sciences Verseon Scancell hVIVO (LON:HVO) and Verona Pharma plc (VRP.L) (LON:VRP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends. Do analysts prefer HVO or VRP? hVIVO presently has a consensus price target of GBX 28, suggesting a potential upside of 178.72%. Given hVIVO's stronger consensus rating and higher possible upside, analysts clearly believe hVIVO is more favorable than Verona Pharma plc (VRP.L).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Verona Pharma plc (VRP.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders hold more shares of HVO or VRP? 34.9% of hVIVO shares are held by institutional investors. 14.0% of hVIVO shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation & earnings, HVO or VRP? hVIVO has higher revenue and earnings than Verona Pharma plc (VRP.L). Verona Pharma plc (VRP.L) is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiohVIVO£68.74M1.03£17.84M£2.424.14Verona Pharma plc (VRP.L)N/AN/AN/A-£32.70N/A Is HVO or VRP more profitable? hVIVO has a net margin of 25.96% compared to Verona Pharma plc (VRP.L)'s net margin of 0.00%. hVIVO's return on equity of 47.93% beat Verona Pharma plc (VRP.L)'s return on equity.Company Net Margins Return on Equity Return on Assets hVIVO25.96% 47.93% 11.97% Verona Pharma plc (VRP.L) N/A N/A N/A Does the media prefer HVO or VRP? In the previous week, hVIVO had 1 more articles in the media than Verona Pharma plc (VRP.L). MarketBeat recorded 1 mentions for hVIVO and 0 mentions for Verona Pharma plc (VRP.L). hVIVO's average media sentiment score of 0.67 beat Verona Pharma plc (VRP.L)'s score of 0.00 indicating that hVIVO is being referred to more favorably in the media. Company Overall Sentiment hVIVO Positive Verona Pharma plc (VRP.L) Neutral SummaryhVIVO beats Verona Pharma plc (VRP.L) on 13 of the 13 factors compared between the two stocks. Get hVIVO News Delivered to You Automatically Sign up to receive the latest news and ratings for HVO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HVO vs. The Competition Export to ExcelMetrichVIVOBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£71.08M£149.58M£5.75B£3.17BDividend Yield1.10%3.74%3.95%5.04%P/E Ratio4.143.8431.31169.05Price / Sales1.034,174.03439.11464,526.94Price / Cash4.9413.1937.7327.93Price / Book1.8170.2910.536.83Net Income£17.84M-£90.99M£3.27B£5.89B7 Day Performance0.46%10.81%1.35%0.15%1 Month Performance-1.99%13.74%6.13%49.89%1 Year Performance-65.83%395.44%49.95%152.06% hVIVO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HVOhVIVO2.4402 of 5 starsGBX 10.05+0.5%GBX 28+178.7%-65.8%£71.08M£68.74M4.14N/ANews CoverageVRPVerona Pharma plc (VRP.L)N/AN/AN/AN/A£228MN/A-1.6822Gap UpAVCTAvacta GroupN/AGBX 48.95-1.1%N/A-26.4%£185.97M£26.29M-6.30120News CoverageGap DownARIXArix BioscienceN/AN/AN/AN/A£183.73M£14.16M1,290.919CIRCircassia GroupN/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap DownBVXPBioventixN/AGBX 2,495+4.0%N/A-40.4%£130.65M£13.65M16.1412Negative NewsOBIOndine BiomedicalN/AC$17.50flatN/A+121.4%C$125.83MC$48.60K-5.27N/AGap Down4BB4basebio1.7494 of 5 starsGBX 930+4.5%GBX 1,600+72.0%-40.0%£119.13M£311K-1,192.31101News CoverageTILSTiziana Life SciencesN/AN/AN/AN/A£113.85M-£3.60M-3.5911VSNVerseonN/AN/AN/AN/A£112.24MN/A-5.17N/AGap UpSCLPScancellN/AGBX 10.29+0.4%N/A-39.7%£106.58MN/A-15.7851 Related Companies and Tools Related Companies VRP Competitors AVCT Competitors ARIX Competitors CIR Competitors BVXP Competitors OBI Competitors 4BB Competitors TILS Competitors VSN Competitors SCLP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:HVO) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding hVIVO plc Please log in to your account or sign up in order to add this asset to your watchlist. Share hVIVO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access